NCT05529134View on ClinicalTrials.gov

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

July 31, 2024

Conditions
Dystrophic Epidermolysis Bullosa
Interventions
DRUG

PTW-002 10 mg/g gel

poloxamer hydrogel for topical administration

DRUG

Placebo

placebo poloxamer hydrogel for topical administration

Trial Locations (3)

45229

Cincinnati Children's Hospital, Cincinnati

94305

Stanford Health Care, Stanford

01655

UMass Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
lead

Phoenicis Therapeutics

INDUSTRY

NCT05529134 - Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene | Biotech Hunter | Biotech Hunter